
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7315118/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2003, 21, 4342-4349.	1.6	2,160
2	Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor. New England Journal of Medicine, 2001, 344, 1052-1056.	27.0	1,926
3	Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer. New England Journal of Medicine, 2006, 354, 809-820.	27.0	1,317
4	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, The, 2013, 381, 295-302.	13.7	1,144
5	Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Human Pathology, 2008, 39, 1411-1419.	2.0	977
6	One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor. JAMA - Journal of the American Medical Association, 2012, 307, 1265.	7.4	832
7	Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncology, The, 2012, 13, 265-274.	10.7	790
8	Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors. Journal of Clinical Oncology, 2006, 24, 4764-4774.	1.6	746
9	Gastrointestinal stromal tumour. Lancet, The, 2013, 382, 973-983.	13.7	518
10	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 2019, 37, 559-569.	1.6	505
11	Management of malignant gastrointestinal stromal tumours. Lancet Oncology, The, 2002, 3, 655-664.	10.7	503
12	Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Research, 2014, 16, 209.	5.0	407
13	Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial. Journal of Clinical Oncology, 2009, 27, 5685-5692.	1.6	406
14	Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Research, 2015, 17, 101.	5.0	291
15	High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. International Journal of Cancer, 1998, 79, 144-146.	5.1	232
16	Gastrointestinal Stromal Tumors. Journal of Clinical Oncology, 2018, 36, 136-143.	1.6	206
17	Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head-and-Neck Cancer: Final Analysis of a Phase I/II Trial. International Journal of Radiation Oncology Biology Physics, 2012, 82, e67-e75.	0.8	192
18	Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. Journal of Clinical Oncology, 2016, 34, 244-250.	1.6	174

#	Article	IF	CITATIONS
19	Risk for Distant Recurrence of Breast Cancer Detected by Mammography Screening or Other Methods. JAMA - Journal of the American Medical Association, 2004, 292, 1064.	7.4	165
20	Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1NOMO breast cancer: a nationwide population-based study. Clinical Cancer Research, 2003, 9, 923-30.	7.0	160
21	Boron neutron capture therapy of brain tumors: clinical trials at the Finnish facility using boronophenylalanine. Journal of Neuro-Oncology, 2003, 62, 123-134.	2.9	156
22	L-type calcium channels regulate filopodia stability and cancer cell invasion downstream of integrin signalling. Nature Communications, 2016, 7, 13297.	12.8	141
23	Effect of <i>KIT</i> and <i>PDGFRA</i> Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib. JAMA Oncology, 2017, 3, 602.	7.1	141
24	Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. Journal of Pathology, 2005, 207, 224-231.	4.5	140
25	<i>KIT</i> and <i>PDGFRA</i> Mutations and the Risk of GI Stromal Tumor Recurrence. Journal of Clinical Oncology, 2015, 33, 634-642.	1.6	139
26	Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. JAMA Oncology, 2018, 4, 1199.	7.1	139
27	Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Research, 2002, 62, 5210-7.	0.9	136
28	Voice Quality After Treatment of Early Vocal Cord Cancer: A Randomized Trial Comparing Laser Surgery With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 255-260.	0.8	133
29	Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, 475-482.	0.8	125
30	The Management of Gastrointestinal Stromal Tumors: A Model for Targeted and Multidisciplinary Therapy of Malignancy. Annual Review of Medicine, 2012, 63, 247-258.	12.2	119
31	Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. Genes Chromosomes and Cancer, 1998, 21, 298-307.	2.8	117
32	Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial. Journal of Clinical Oncology, 2012, 30, 11-18.	1.6	114
33	Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors. JAMA Oncology, 2020, 6, 1241.	7.1	111
34	Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treatment Reviews, 2011, 37, 75-88.	7.7	108
35	Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncology, The, 2015, 16, 1700-1710.	10.7	108
36	Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription. Nature Communications, 2016, 7, 12237.	12.8	105

#	Article	IF	CITATIONS
37	A High Pretreatment Serum Basic Fibroblast Growth Factor Concentration Is an Independent Predictor of Poor Prognosis in Non-Hodgkin's Lymphoma. Blood, 1999, 94, 3334-3339.	1.4	102
38	Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Research and Treatment, 1999, 53, 161-166.	2.5	99
39	Tyrosine kinase inhibitor imatinib (STIS71) as an anticancer agent for solid tumours. Annals of Medicine, 2001, 33, 451-455.	3.8	94
40	Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer and Tumors ≤2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. Journal of Clinical Oncology, 2015, 33, 2600-2608.	1.6	91
41	CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. Cancer Research, 2017, 77, 5652-5663.	0.9	90
42	Breast cancer outcome prediction with tumour tissue images and machine learning. Breast Cancer Research and Treatment, 2019, 177, 41-52.	2.5	80
43	Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer. JAMA Oncology, 2017, 3, 793.	7.1	74
44	Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. Breast Cancer Research, 2018, 20, 15.	5.0	71
45	Elevated Levels of StAR-Related Lipid Transfer Protein 3 Alter Cholesterol Balance and Adhesiveness of Breast Cancer Cells. American Journal of Pathology, 2015, 185, 987-1000.	3.8	68
46	Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology, The, 2009, 10, 1145-1151.	10.7	65
47	Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer, 2014, 120, 2325-2333.	4.1	65
48	HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clinical Cancer Research, 2017, 23, 4323-4334.	7.0	64
49	Late mortality from pT1N0M0 breast carcinoma. Cancer, 1999, 85, 2183-2189.	4.1	61
50	Adjuvant treatment of GIST: patient selection and treatment strategies. Nature Reviews Clinical Oncology, 2012, 9, 351-358.	27.6	60
51	Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy. Nature Communications, 2019, 10, 620.	12.8	60
52	Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes and Cancer, 1997, 18, 286-291.	2.8	57
53	Sunitinib for imatinib-resistant GIST. Lancet, The, 2006, 368, 1303-1304.	13.7	56
54	Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. BMC Cancer, 2018, 18, 504.	2.6	56

#	Article	IF	CITATIONS
55	Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study. Acta Oncológica, 2016, 55, 188-192.	1.8	55
56	Systemic chemotherapy for cancer: from weapon to treatment. Lancet Oncology, The, 2008, 9, 304.	10.7	52
57	Cytochrome P450?inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clinical Pharmacology and Therapeutics, 1999, 66, 589-593.	4.7	50
58	Evidence for false aneuploid peaks in flow cytometric analysis of paraffin-embedded tissue. Cytometry, 1990, 11, 431-437.	1.8	49
59	SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nature Communications, 2019, 10, 2340.	12.8	49
60	Sunitinibâ€induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. BJU International, 2016, 117, 110-117.	2.5	47
61	A Novel Anti-HER2 Antibody–Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine. Molecular Cancer Therapeutics, 2019, 18, 1721-1730.	4.1	47
62	Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. BMC Medicine, 2015, 13, 177.	5.5	45
63	Amplification of c-myc Oncogene by Chromogenic and Fluorescence In Situ Hybridization in Archival Breast Cancer Tissue Array Samples. Laboratory Investigation, 2001, 81, 1545-1551.	3.7	44
64	Boron neutron capture therapy (BNCT) followed by intensity modulated chemoradiotherapy as primary treatment of large head and neck cancer with intracranial involvement. Radiotherapy and Oncology, 2011, 99, 98-99.	0.6	44
65	Cancer in Young Adults With Ischemic Stroke. Stroke, 2015, 46, 1601-1606.	2.0	44
66	Loss of <i>ARID1A</i> Activates <i>ANXA1</i> , which Serves as a Predictive Biomarker for Trastuzumab Resistance. Clinical Cancer Research, 2016, 22, 5238-5248.	7.0	43
67	Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma: An analysis of dose response and survival. Radiotherapy and Oncology, 2019, 137, 153-158.	0.6	43
68	Molecular characterization of deletion at 11q22.1â€⊋3.3 in mantle cell lymphoma. British Journal of Haematology, 1999, 104, 665-671.	2.5	41
69	Amplification of c-myc by Fluorescence In Situ Hybridization in a Population-Based Breast Cancer Tissue Array. Modern Pathology, 2001, 14, 1030-1035.	5.5	40
70	Paclitaxel-induced apoptotic changes followed by time-lapse video microscopy in cell lines established from head and neck cancer. Journal of Cancer Research and Clinical Oncology, 1996, 122, 214-218.	2.5	39
71	Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour – Does it increase the risk for tumour cell seeding and recurrence?. European Journal of Cancer, 2016, 59, 128-133.	2.8	39
72	ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. Cancer Letters, 2020, 473, 156-163.	7.2	39

#	Article	IF	CITATIONS
73	BCL2 Overexpression in Diffuse Large B-Cell Lymphoma. Leukemia and Lymphoma, 1999, 34, 45-52.	1.3	38
74	Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization. EMBO Molecular Medicine, 2019, 11, .	6.9	38
75	Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma. Haematologica, 2014, 99, e193-e196.	3.5	37
76	Phase lb/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors Journal of Clinical Oncology, 2018, 36, 3014-3014.	1.6	36
77	Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study. Radiotherapy and Oncology, 2015, 116, 233-238.	0.6	34
78	Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry. Breast Cancer Research and Treatment, 2016, 157, 437-446.	2.5	33
79	Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. British Journal of Cancer, 2017, 117, 1278-1285.	6.4	33
80	Drug-Sensitivity Screening and Genomic Characterization of 45 HPV-Negative Head and Neck Carcinoma Cell Lines for Novel Biomarkers of Drug Efficacy. Molecular Cancer Therapeutics, 2018, 17, 2060-2071.	4.1	33
81	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. Npj Breast Cancer, 2022, 8, 3.	5.2	33
82	Cardiac toxicity of sunitinib. Lancet, The, 2007, 370, 1978-1980.	13.7	31
83	Increased pancreatic cancer risk following radiotherapy for testicular cancer. British Journal of Cancer, 2016, 115, 901-908.	6.4	30
84	Boron Neutron Capture Therapy in the Treatment of Recurrent Laryngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 404-410.	0.8	29
85	An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®. Breast Cancer Research, 2017, 19, 55.	5.0	29
86	Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncológica, 2005, 44, 23-31.	1.8	27
87	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. Oncologist, 2015, 20, 823-830.	3.7	26
88	CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis. Cancer Research, 2021, 81, 4319-4331.	0.9	26
89	Accelerator-based boron neutron capture therapy facility at the Helsinki University Hospital. Acta Oncolųgica, 2022, 61, 269-273.	1.8	26
90	Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes Journal of Clinical Oncology, 2013, 31, 10503-10503.	1.6	26

#	Article	IF	CITATIONS
91	Escalating and de-escalating treatment in HER2-positive early breast cancer. Cancer Treatment Reviews, 2017, 52, 1-11.	7.7	24
92	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. European Journal of Cancer, 2015, 51, 852-860.	2.8	23
93	Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncológica, 2014, 53, 186-194.	1.8	22
94	Compressive stress-mediated p38 activation required for ERα + phenotype in breast cancer. Nature Communications, 2021, 12, 6967.	12.8	22
95	Second line therapies for the treatment of gastrointestinal stromal tumor. Current Opinion in Oncology, 2007, 19, 353-358.	2.4	21
96	Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. Cancer Research, 2016, 76, 264-274.	0.9	21
97	Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial. Clinical Cancer Research, 2020, 26, 2603-2614.	7.0	20
98	Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma. PLoS ONE, 2016, 11, e0153745.	2.5	20
99	Endotoxins induce and interferonâ€Î± suppresses vascular endothelial growth factor (VEGF) production in human peripheral blood mononuclear cells. FASEB Journal, 2001, 15, 1318-1320.	0.5	18
100	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naÃ ⁻ ve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. European Urology Focus, 2017, 3, 606-614.	3.1	18
101	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clinical Cancer Research, 2022, 28, 1672-1679.	7.0	18
102	Title is missing!. Journal of Neuro-Oncology, 2003, 62, 123-134.	2.9	17
103	Adjuvant Therapy for High-Risk Gastrointestinal Stromal Tumour. Drugs, 2012, 72, 1953-1963.	10.9	17
104	Prognostic value of isolated tumour cells in sentinel lymph nodes in early-stage breast cancer: a prospective study. British Journal of Cancer, 2018, 118, 1529-1535.	6.4	17
105	Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment. PLoS ONE, 2018, 13, e0193048.	2.5	17
106	Challenges of international oncology trial collaboration—a call to action. British Journal of Cancer, 2019, 121, 515-521.	6.4	17
107	Extracellular vesicles as modifiers of antibodyâ€drug conjugate efficacy. Journal of Extracellular Vesicles, 2021, 10, e12070.	12.2	17
108	PPP2R1BGene in Chronic Lymphocytic Leukemias and Mantle Cell Lymphomas. Leukemia and Lymphoma, 2001, 41, 177-183.	1.3	16

#	Article	IF	CITATIONS
109	Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer, 2017, 15, 487-494.	1.9	16
110	Gastrointestinal Stromal Tumor: A Method for Optimizing the Timing of CT Scans in the Follow-up of Cancer Patients. Radiology, 2014, 271, 96-106.	7.3	15
111	Early Pregnancy Sex Steroids and Maternal Breast Cancer: A Nested Case–Control Study. Cancer Research, 2014, 74, 6958-6967.	0.9	15
112	Anagrelide for Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2019, 25, 1676-1687.	7.0	14
113	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. Oncotarget, 2015, 6, 30306-30316.	1.8	14
114	Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. Journal of Clinical Oncology, 2022, , JCO2102054.	1.6	14
115	Gastrointestinal Stromal Tumors. Hematology/Oncology Clinics of North America, 2013, 27, 889-904.	2.2	13
116	Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects. Radiation Research, 2017, 187, 186.	1.5	13
117	SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour. British Journal of Cancer, 2017, 116, 1195-1202.	6.4	13
118	Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours. Journal of Cellular and Molecular Medicine, 2018, 22, 2220-2230.	3.6	13
119	Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1092-1101.	6.4	13
120	Reactive stroma and trastuzumab resistance in HER2â€positive early breast cancer. International Journal of Cancer, 2020, 147, 266-276.	5.1	13
121	Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients. European Journal of Cancer, 2022, 166, 185-201.	2.8	13
122	Serum CD44 in Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1999, 33, 433-440.	1.3	12
123	Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer. Cancers, 2021, 13, 3892.	3.7	11
124	High preâ€ŧreatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small ell lung cancer. International Journal of Cancer, 1998, 79, 144-146.	5.1	11
125	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (CIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial Journal of Clinical Oncology, 2012, 30, LBA10008-LBA10008.	1.6	11
126	Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients. British Journal of Cancer, 2022, 126, 1401-1409.	6.4	11

#	Article	IF	CITATIONS
127	Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial Journal of Clinical Oncology, 2012, 30, 507-507.	1.6	10
128	Treatment Results of Nasopharyngeal Cancer a nationwide survey from Finland. Acta Oncológica, 1996, 35, 697-702.	1.8	9
129	Prognostic Impact of Immunoglobulin Kappa C (IGKC) in Early Breast Cancer. Cancers, 2021, 13, 3626.	3.7	9
130	Final overall survival (OS) analysis with modeling of crossover impact in the phase III GRID trial of regorafenib vs placebo in advanced gastrointestinal stromal tumors (GIST) Journal of Clinical Oncology, 2016, 34, 156-156.	1.6	9
131	ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST) Journal of Clinical Oncology, 2019, 37, 11023-11023.	1.6	9
132	Stomach cancer risk following radiotherapy for testicular cancer Journal of Clinical Oncology, 2013, 31, 4536-4536.	1.6	9
133	Clinical significance of circulating CD44 in non-Hodgkin's lymphoma. , 1998, 79, 221-225.		8
134	Unusually young Merkel cell carcinoma patients are Merkel cell polyomavirus positive and frequently immunocompromised. European Journal of Plastic Surgery, 2010, 33, 349-353.	0.6	8
135	p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial. Clinical Cancer Research, 2018, 24, 3046-3052.	7.0	8
136	Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec). Medizinische Klinik, 2002, 97 Suppl 1, 28-30.	0.3	8
137	Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort. Cancer Research, 2017, 77, 134-141.	0.9	7
138	ANO1 Expression Orchestrates p27Kip1/MCL1-Mediated Signaling in Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 1170.	3.7	7
139	An updated overall survival analysis with correction for protocol-planned crossover of the international, phase III, randomized, placebo-controlled trial of regorafenib in advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID) Journal of Clinical Oncology. 2015, 33, 110-110.	1.6	7
140	Effects of immune architecture on response to adjuvant capecitabine in triple-negative breast cancer (FinXX trial) Journal of Clinical Oncology, 2019, 37, 3142-3142.	1.6	7
141	Novel cancer therapies: more efficacy, less toxicity and improved organ preservation. Annals of Medicine, 2000, 32, 31-33.	3.8	6
142	Serum CD44 Levels Preceding the Diagnosis of Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2000, 37, 585-592.	1.3	6
143	Management of small gastrointestinal stromal tumours – Authors' reply. Lancet, The, 2013, 382, 1701-1702.	13.7	6
144	Stage I Non-Hodgkin's Lymphoma Treated with Doxorubicin-containing Chemotherapy with or without Radiotherapy. Acta Oncológica, 1997, 36, 619-624.	1.8	5

HEIKKI TUOMAS JOENSUU

#	Article	IF	CITATIONS
145	Duration of adjuvant trastuzumab: shorter beats longer. Lancet, The, 2013, 382, 1010-1011.	13.7	5
146	ERBB4 Promoter Polymorphism Is Associated with Poor Distant Disease-Free Survival in High-Risk Early Breast Cancer. PLoS ONE, 2014, 9, e102388.	2.5	5
147	Consumption of Lactose, Other FODMAPs and Diarrhoea during Adjuvant 5-Fluorouracil Chemotherapy for Colorectal Cancer. Nutrients, 2020, 12, 407.	4.1	5
148	Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors â‰⊉cm: A meta-analysis of the randomized trastuzumab trials Journal of Clinical Oncology, 2014, 32, 508-508.	1.6	5
149	Tumor PIK3CA genotype and prognosis: A pooled analysis of 4,241 patients (pts) with early-stage breast cancer (BC) Journal of Clinical Oncology, 2015, 33, 516-516.	1.6	5
150	Dual targeting of HER2 with lapatinib and trastuzumab. Lancet Oncology, The, 2014, 15, 1050-1052.	10.7	3
151	LUX-breast 3: Randomized phase II study of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases (BM) after trastuzumab or lapatinib-based therapy Journal of Clinical Oncology, 2012, 30, TPS647-TPS647.	1.6	3
152	Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial Journal of Clinical Oncology, 2016, 34, 1001-1001.	1.6	3
153	Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up Journal of Clinical Oncology, 2020, 38, 11503-11503.	1.6	3
154	Fibrinogenâ€like protein 2 in gastrointestinal stromal tumour. Journal of Cellular and Molecular Medicine, 2022, 26, 1083-1094.	3.6	3
155	MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1/OCT4 levels. IScience, 2022, 25, 104459.	4.1	3
156	Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up. Acta Oncológica, 2020, 59, 1064-1071.	1.8	2
157	High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. , 1998, 79, 144.		2
158	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial Journal of Clinical Oncology, 2012, 30, LBA10008-LBA10008.	1.6	2
159	Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis Journal of Clinical Oncology, 2014, 32, 23-23.	1.6	2
160	Role of intratumoral NK cells in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort Journal of Clinical Oncology, 2020, 38, 510-510.	1.6	2
161	Special Section: Autologous Stem Cell Transplantations in Solid Tumours: Autologous Stem Cell Transplantation in Breast Cancer. Annals of Medicine, 1996, 28, 145-149.	3.8	1

162 HERA crosses over. Lancet Oncology, The, 2011, 12, 203-204.

10.7 1

#	Article	IF	CITATIONS
163	Physician Estimations of the Risk of Gastrointestinal Stromal Tumor Recurrence—Not Accurate Enough?. JAMA Oncology, 2015, 1, 805.	7.1	1
164	Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor 2-Positive Breast Cancer—Reply. JAMA Oncology, 2019, 5, 118.	7.1	1
165	Long-term efficacy and safety of androgen receptor inhibitor ODM-201 in ARADES phase I/II trial Journal of Clinical Oncology, 2014, 32, 5079-5079.	1.6	1
166	Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics Journal of Clinical Oncology, 2013, 31, 10551-10551.	1.6	1
167	Long-Term Survival Outcomes of Patients with Small (â‰⊈ cm) Node-Negative HER2-Positive Breast Cancer Not Treated with Adjuvant Anti-HER2-Targeted Therapy: A 10-Year Follow-Up Study. Breast Care, 2022, 17, 279-287.	1.4	1
168	Comparison of Photon Isoeffective Dose Models Based on In Vitro and In Vivo Radiobiological Experiments for Head and Neck Cancer Treated with BNCT. Radiation Research, 2022, 198, .	1.5	1
169	Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor who are in complete radiological remission: A prospective multicenter phase II study Journal of Clinical Oncology, 2022, 40, 11535-11535.	1.6	1
170	Reply to P.A. Leppäioto. Journal of Clinical Oncology, 2009, 27, 3066-3067.	1.6	0
171	Reply to M. Isik et al. Journal of Clinical Oncology, 2010, 28, e335-e336.	1.6	0
172	Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice. International Journal of Cancer, 2016, 139, 2270-2276.	5.1	0
173	Taxane Followed by Anthracycline or Vice Versa: Impact of Sequential Order on Breast Cancer Recurrence?—Reply. JAMA Oncology, 2018, 4, 423.	7.1	0
174	Risk of Treatment-Related Stomach Cancer Among Hodgkin Lymphoma Survivors. Blood, 2010, 116, 2679-2679.	1.4	0
175	Correlation of endothelial angiopoietin-2 expression with tumor angiogenesis and response to sunitinib in metastatic renal cell carcinoma Journal of Clinical Oncology, 2015, 33, 461-461.	1.6	0
176	Role of adjuvant imatinib dose in radically resected GIST harboring KIT exon 9 mutations Journal of Clinical Oncology, 2020, 38, 11533-11533.	1.6	0
177	Sarcoma and Gastrointestinal Stromal Tumors. , 0, , 227-258.		0
178	Rapid Absorption of Naloxone from Eye Drops. Pharmaceuticals, 2022, 15, 532.	3.8	0